
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1478202/publications.pdf Version: 2024-02-01



RDIAN LARDAHAM

#	Article	IF	CITATIONS
1	EP300 Selectively Controls the Enhancer Landscape of <i>MYCN</i> -Amplified Neuroblastoma. Cancer Discovery, 2022, 12, 730-751.	7.7	64
2	SEAseq: a portable and cloud-based chromatin occupancy analysis suite. BMC Bioinformatics, 2022, 23, 77.	1.2	3
3	The nuclear receptor THRB facilitates differentiation of human PSCs into more mature hepatocytes. Cell Stem Cell, 2022, 29, 795-809.e11.	5.2	5
4	Intrinsic transcriptional heterogeneity in neuroblastoma guides mechanistic and therapeutic insights. Cell Reports Medicine, 2022, 3, 100632.	3.3	12
5	BRD2 interconnects with BRD3 to facilitate Pol II transcription initiation and elongation to prime promoters for cell differentiation. Cellular and Molecular Life Sciences, 2022, 79, .	2.4	9
6	Cell-specific transcriptional control of mitochondrial metabolism by TIF1γ drives erythropoiesis. Science, 2021, 372, 716-721.	6.0	25
7	Super-enhancer-based identification of a BATF3/IL-2Râ^ module reveals vulnerabilities in anaplastic large cell lymphoma. Nature Communications, 2021, 12, 5577.	5.8	21
8	MEIS2 Is an Adrenergic Core Regulatory Transcription Factor Involved in Early Initiation of TH-MYCN-Driven Neuroblastoma Formation. Cancers, 2021, 13, 4783.	1.7	12
9	Retinoic acid rewires the adrenergic core regulatory circuitry of childhood neuroblastoma. Science Advances, 2021, 7, eabe0834.	4.7	22
10	Predicting master transcription factors from pan-cancer expression data. Science Advances, 2021, 7, eabf6123.	4.7	30
11	Synergistic Anti-Tumor Effect of Combining Selective CDK7 and BRD4 Inhibition in Neuroblastoma. Frontiers in Oncology, 2021, 11, 773186.	1.3	11
12	Common variants in signaling transcription-factor-binding sites drive phenotypic variability in red blood cell traits. Nature Genetics, 2020, 52, 1333-1345.	9.4	24
13	ARID1A loss in neuroblastoma promotes the adrenergic-to-mesenchymal transition by regulating enhancer-mediated gene expression. Science Advances, 2020, 6, eaaz3440.	4.7	47
14	CHD7 and Runx1 interaction provides a braking mechanism for hematopoietic differentiation. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 23626-23635.	3.3	18
15	RNA helicase DDX21 mediates nucleotide stress responses in neural crest and melanoma cells. Nature Cell Biology, 2020, 22, 372-379.	4.6	37
16	LIN28B regulates transcription and potentiates MYCN-induced neuroblastoma through binding to ZNF143 at target gene promotors. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 16516-16526.	3.3	31
17	Cdk1 Controls Global Epigenetic Landscape in Embryonic Stem Cells. Molecular Cell, 2020, 78, 459-476.e13.	4.5	76
18	PolÂII phosphorylation regulates a switch between transcriptional and splicing condensates. Nature, 2019, 572, 543-548.	13.7	457

#	Article	IF	CITATIONS
19	Mediator Condensates Localize Signaling Factors to Key Cell Identity Genes. Molecular Cell, 2019, 76, 753-766.e6.	4.5	188
20	ASCL1 is a MYCN- and LMO1-dependent member of the adrenergic neuroblastoma core regulatory circuitry. Nature Communications, 2019, 10, 5622.	5.8	56
21	Cross-Cohort Analysis Identifies a TEAD4–MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma. Cancer Discovery, 2018, 8, 582-599.	7.7	119
22	EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma. Cancer Cell, 2018, 33, 202-216.e6.	7.7	116
23	<i>MYC</i> Drives a Subset of High-Risk Pediatric Neuroblastomas and Is Activated through Mechanisms Including Enhancer Hijacking and Focal Enhancer Amplification. Cancer Discovery, 2018, 8, 320-335.	7.7	172
24	High MITF Expression Is Associated with Super-Enhancers and Suppressed by CDK7 Inhibition in Melanoma. Journal of Investigative Dermatology, 2018, 138, 1582-1590.	0.3	46
25	Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression. Cancer Discovery, 2018, 8, 59-73.	7.7	96
26	Transcription Factors Activate Genes through the Phase-Separation Capacity of Their Activation Domains. Cell, 2018, 175, 1842-1855.e16.	13.5	1,195
27	Coactivator condensation at super-enhancers links phase separation and gene control. Science, 2018, 361, .	6.0	1,687
28	JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia. Journal of Experimental Medicine, 2018, 215, 1929-1945.	4.2	22
29	Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry. Nature Genetics, 2018, 50, 1240-1246.	9.4	199
30	Activation of the LMO2 oncogene through a somatically acquired neomorphic promoter in T-cell acute lymphoblastic leukemia. Blood, 2017, 129, 3221-3226.	0.6	61
31	APOBEC signature mutation generates an oncogenic enhancer that drives LMO1 expression in T-ALL. Leukemia, 2017, 31, 2057-2064.	3.3	54
32	Small genomic insertions form enhancers that misregulate oncogenes. Nature Communications, 2017, 8, 14385.	5.8	76
33	Integrated genomic analyses of de novo pathways underlying atypical meningiomas. Nature Communications, 2017, 8, 14433.	5.8	156
34	The long noncoding RNA <i>Wisper</i> controls cardiac fibrosis and remodeling. Science Translational Medicine, 2017, 9, .	5.8	232
35	A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer. Nature Communications, 2017, 8, 14802.	5.8	168
36	Genome-wide Trans-ethnic Meta-analysis Identifies Seven Genetic Loci Influencing Erythrocyte Traits and a Role for RBPMS in Erythropoiesis. American Journal of Human Genetics, 2017, 100, 51-63.	2.6	45

#	Article	IF	CITATIONS
37	TOX Regulates Growth, DNA Repair, and Genomic Instability in T-cell Acute Lymphoblastic Leukemia. Cancer Discovery, 2017, 7, 1336-1353.	7.7	48
38	Activation of the p53 Transcriptional Program Sensitizes Cancer Cells to Cdk7 Inhibitors. Cell Reports, 2017, 21, 467-481.	2.9	65
39	YY1 Is a Structural Regulator of Enhancer-Promoter Loops. Cell, 2017, 171, 1573-1588.e28.	13.5	749
40	Parkinson-associated risk variant in distal enhancer of α-synuclein modulates target gene expression. Nature, 2016, 533, 95-99.	13.7	466
41	O-GlcNAcase Is an RNA Polymerase II Elongation Factor Coupled to Pausing Factors SPT5 and TIF1β. Journal of Biological Chemistry, 2016, 291, 22703-22713.	1.6	35
42	Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. Nature Chemical Biology, 2016, 12, 876-884.	3.9	249
43	Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas. Nature Genetics, 2016, 48, 1253-1259.	9.4	265
44	Models of human core transcriptional regulatory circuitries. Genome Research, 2016, 26, 385-396.	2.4	223
45	Abstract 2441: CDK12/13 inhibition cooperates with the Ewing sarcoma oncoprotein EWS/FLI to attenuate homologous recombination repair in Ewing sarcoma cells. , 2016, , .		1
46	Convergence of Developmental and Oncogenic Signaling Pathways at Transcriptional Super-Enhancers. Molecular Cell, 2015, 58, 362-370.	4.5	382
47	Chromatin proteomic profiling reveals novel proteins associated with histone-marked genomic regions. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 3841-3846.	3.3	123
48	CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer. Cell, 2015, 163, 174-186.	13.5	346
49	Transcription factor trapping by RNA in gene regulatory elements. Science, 2015, 350, 978-981.	6.0	389
50	Genetic predisposition to neuroblastoma mediated by a LMO1 super-enhancer polymorphism. Nature, 2015, 528, 418-421.	13.7	263
51	Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor. Cancer Cell, 2014, 26, 909-922.	7.7	376
52	CDK7 Inhibition Suppresses Super-Enhancer-Linked Oncogenic Transcription in MYCN-Driven Cancer. Cell, 2014, 159, 1126-1139.	13.5	498
53	An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science, 2014, 346, 1373-1377.	6.0	665
54	Novel Mechanism of Positive versus Negative Regulation by Thyroid Hormone Receptor β1 (TRβ1) Identified by Genome-wide Profiling of Binding Sites in Mouse Liver. Journal of Biological Chemistry, 2014, 289, 1313-1328.	1.6	92

#	Article	IF	CITATIONS
55	Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature, 2014, 511, 616-620.	13.7	698
56	The Developmental Potential of iPSCs Is Greatly Influenced by Reprogramming Factor Selection. Cell Stem Cell, 2014, 15, 295-309.	5.2	137
57	Control of Cell Identity Genes Occurs in Insulated Neighborhoods in Mammalian Chromosomes. Cell, 2014, 159, 374-387.	13.5	793
58	Dynamic regulation of epigenomic landscapes during hematopoiesis. BMC Genomics, 2013, 14, 193.	1.2	41
59	Super-Enhancers in the Control of Cell Identity and Disease. Cell, 2013, 155, 934-947.	13.5	2,916
60	Multiple Structural Maintenance of Chromosome Complexes at Transcriptional Regulatory Elements. Stem Cell Reports, 2013, 1, 371-378.	2.3	113
61	Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes. Cell, 2013, 153, 307-319.	13.5	3,202
62	Genome-wide incorporation dynamics reveal distinct categories of turnover for the histone variant H3.3. Genome Biology, 2013, 14, R121.	13.9	123
63	Genome-wide Analyses of Transcription Factor GATA3-Mediated Gene Regulation in Distinct T Cell Types. Immunity, 2011, 35, 299-311.	6.6	293